Our d150 hCSs showed more stem-cell survival, and less proliferative TOP2A-positive and more early PAX6-positive NPC populations than the d94 hCSs of Madhavan et al. [10], who used a protocol most similar to ours. The gene discussed is PAX6; the disease is nasopharyngeal carcinoma.